Thrivent Financial for Lutherans Has $6.42 Million Stock Holdings in Elevance Health, Inc. $ELV

Thrivent Financial for Lutherans lessened its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 8.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 18,309 shares of the company’s stock after selling 1,586 shares during the period. Thrivent Financial for Lutherans’ holdings in Elevance Health were worth $6,416,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Physician Wealth Advisors Inc. grew its holdings in Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after acquiring an additional 63 shares during the period. Rossby Financial LCC grew its holdings in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares during the period. Activest Wealth Management grew its holdings in Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after acquiring an additional 34 shares during the period. ORG Partners LLC grew its holdings in Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after acquiring an additional 59 shares during the period. Finally, Dorato Capital Management acquired a new stake in Elevance Health during the 4th quarter worth $41,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of NYSE ELV opened at $396.18 on Thursday. The firm has a market cap of $86.04 billion, a PE ratio of 16.85, a PEG ratio of 2.29 and a beta of 0.66. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $411.31. The company has a fifty day moving average price of $329.59 and a 200 day moving average price of $335.33.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the prior year, the business earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Research analysts predict that Elevance Health, Inc. will post 26.8 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a $1.72 dividend. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s dividend payout ratio is presently 29.26%.

Analyst Upgrades and Downgrades

A number of research firms have commented on ELV. JPMorgan Chase & Co. lifted their target price on shares of Elevance Health from $397.00 to $411.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. UBS Group set a $400.00 price target on shares of Elevance Health in a report on Thursday, January 29th. Wells Fargo & Company decreased their price target on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a report on Friday, January 30th. The Goldman Sachs Group lifted their target price on Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Finally, Evercore reiterated a “hold” rating on shares of Elevance Health in a report on Tuesday. Fourteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $396.16.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.